Red Light ships five kg psilocybin to Irvine Labs

Executive Summary

• Red Light Holland successfully shipped a second, larger 5kg batch of naturally occurring psilocybin to its R&D partner, Irvine Labs, under a US Controlled Substances import permit, marking a significant scaling milestone following the initial July 2025 shipment.
• The shipment supports expanded R&D activities, including validation of proprietary dehydration and packaging processes to extend shelf life for potential medical-grade applications.
• The company concurrently announced the issuance of 3,250,719 common shares to settle debts with arm's-length creditors at a deemed price of 3.5 cents per share.

Key Details

• Shipment Details:
  • Quantity: 5 kilograms of natural psilocybin.
  • Origin: Facility in the Netherlands.
  • Destination: Irvine Labs Inc. in California, USA.
  • Regulatory Status: Shipped via USA Controlled Substances import permit; Irvine Labs is FDA-compliant and DEA-registered.
  • Context: Second shipment; follows initial groundbreaking shipment in July 2025.
• Operational Impact:
  • Validates compatibility with medical-grade manufacturing applications.
  • Supports scaling of the partnership and collaborative efforts toward standardized psilocybin products.
  • Enables further validation of proprietary dehydration and packaging processes designed to maintain product integrity and extend shelf life.
• Financing/Debt Settlement:
  • Instrument: Issuance of common shares.
  • Quantity: 3,250,719 shares.
  • Price: Deemed price of 3.5 cents per share.
  • Counterparties: Arm's-length creditors.
  • Purpose: Settlement of debt.

Notable Quotes

• Todd Shapiro, CEO and Director, Red Light Holland: "This second and larger shipment represents significant progress in scaling our R&D operations... Moving from our initial shipment to this substantially larger five kg export demonstrates both the strength of our partnership with Irvine Labs and the viability of our supply chain for potential therapeutic applications."
• Shaun Land, President, Irvine Labs: "This larger shipment allows us to conduct more comprehensive testing of our preservation processes. Our 2025 DEA quota allocation continues to support the scaling of this important research, and we're excited to advance toward standardized products for emerging therapeutic markets."